...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of dermatology >Results of a retrospective study on the efficacy and safety of adalimumab 80?mg administrated every other week in patients with psoriasis at a single Japanese institution
【24h】

Results of a retrospective study on the efficacy and safety of adalimumab 80?mg administrated every other week in patients with psoriasis at a single Japanese institution

机译：回顾性研究患者在单一日本机构的牛皮癣患者中每隔一周施用Adalimalab 80的疗效和安全性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Adalimumab ( ADA ) is one of the tumor necrosis factor ( TNF )‐α monoclonal antibodies used for the treatment of psoriasis. In Japan, standard dosing of ADA for adults is an initial s.c. injection of 80?mg, followed by 40?mg every other week. Some patients who initially do not respond to treatment are allowed an increased dose of 80?mg every other week. However, studies on the efficacy and safety of ADA dose escalation to 80?mg every other week are few. In this study, we retrospectively studied 92 patients with psoriasis who received ADA therapy in our hospital. In 45 out of 92 patients, the dose of ADA 80?mg was administrated every other week, and the efficacy was observed within 12?weeks. The most common adverse drug reaction was upper respiratory infection, followed by diarrhea. In three patients, malignancies occurred during the observation period. No deaths or other severe complications were observed. In conclusion, this study showed the efficacy and safety of ADA dose escalation to 80?mg every other week in patients with psoriasis.
机译：摘要Adalimumab（ADA）是用于治疗牛皮癣的肿瘤坏死因子（TNF）-α单克隆抗体之一。在日本，成人的标准给药是初始的S.C.注射80毫克，随后每隔一周40毫克。一些患者最初没有响应治疗的患者每隔一周允许每隔80毫克的剂量增加。然而，关于ADA剂量升级的疗效和安全性每隔一周的疗效和安全性的研究很少。在这项研究中，我们回顾性地研究了92例患有牛皮癣患者，在医院接受了ADA治疗。在92名患者中有45例，ADA 80？MG的剂量每隔一周施用，并且在12℃内观察到疗效。最常见的不良药物反应是上呼吸道感染，其次是腹泻。在三名患者中，在观察期间发生恶性肿瘤。没有观察到死亡或其他严重的并发症。总之，本研究表明，牛皮癣患者的每隔一周，ADA剂量升级至80毫克的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号